Principal Investigator: Panos Kanavos 
Start Date: 01 January 2018
End Date: 31 December 2020
Region: Europe
Keywords: health technology assessment, rare diseases, medical devices, value for money, burden of disease, disease severity, capacity building of HTA, value assessment, efficiency in resource allocation, health technology regulation & assessment 

The Impact HTA project was funded by the European Commission under the Horizon2020 Framework Programme. LSE Health led the consortium of 15 institutional partners, which combined geographical and disciplinary diversity with academic rigor and policy relevance emphasised by the members’ experience in linking research to policy.

IMPACT HTA placed strong emphasis on methodological improvements in the conduct of HTA and aimed at producing tangible deliverables and toolkits that are immediately actionable by health care decision-makers and HTA agencies. Specifically, the overall objectives of IMPACT HTA were:

• To contribute to the understanding of variations in costs and health outcomes within and across countries, the rationale and criteria for decision-making across different settings as well as the factors and preferences that shape HTA recommendations;
• To develop and disseminate innovative methodologies, toolkits and processes aiming to aid decision-making and improve efficiency in resource allocation in a number of areas including: extrapolation from RCT data; the development of a common and comparable dataset on health and social care costs across EU countries; quality of life measurement with emphasis on patient preference elicitation; methods of value assessment of medical technologies, including multi-criteria decision analysis; and how non-randomised studies can inform health economic evaluations; and
• To develop and disseminate tools facilitating EU-wide collaboration across Member State governments, HTA agencies, health care professionals, patients and the broader stakeholder community.

The thematic areas of focus of IMPACT HTA included:

• The use of randomized controlled trial (RCT) and observational/registry data in economic evaluation;
• The development of a costing methodology and a creation of a core dataset of (health and social care) costs for facilitating cross border comparisons in economic evaluation;
• Capturing health preferences across different patient diagnoses using the EQ-5D-5L;
• The analysis and interpretation of non-randomised studies to inform health economic evaluation;
• The use of multi-criteria value methods and their relevance for HTA decision-making;
• Economic evaluation methods for hospital-based assessments;
• Measuring the fiscal impact of new healthcare interventions and incorporating this into HTA processes; and
• HTA appraisal for orphan medicinal products.